⌘K
t
SkinBioTherapeutics plc confirmed on 18 December 2025 that trading for the new financial year started positively, and its Board anticipates reporting 2026 full-year numbers in line with market expectations. These market expectations for the year ending 30 June 2026 are revenue of £6.2 million and adjusted EBITDA of £0.7 million. Additionally, the Company's Directors provided a Q&A within the Shareholder Circulars section of its Shareholder Information page regarding the upcoming AGM.
| Date | 18 Dec 2025 |
| Time | 07:00:08 |
| Category | Miscellaneous |
| ID | 0254M |
SkinBioTherapeutics plc
("SkinBioTherapeutics" or the "Group" or the "Company")
Reconfirmation of Market Guidance and AGM Shareholder Information
18 December 2025 - SkinBioTherapeutics plc (AIM: SBTX), a life science group focused on skin health, confirms that overall trading of the Group has started very positively for the new financial year. Consequently, the Board still anticipates reporting 2026 full year numbers in line with market expectations*.
In addition, in response to some shareholder questions about the upcoming AGM, the Directors have provided a Q&A within the Shareholder Circulars section of the Shareholder Information page [Here].
* Market expectations for the year ending 30 June 2026: revenue of £6.2 million and adjusted EBITDA of £0.7 million
-Ends-
For more information please contact:
|
SkinBioTherapeutics plc Stuart J. Ashman, CEO |
+44 (0) 191 495 7325
|
|
Singer Capital Markets (Nominated Adviser & Broker) Philip Davies |
+44 (0) 020 7496 3000
|
|
Vigo Consulting (financial press) Rozi Morris, Melanie Toyne-Sewell
|
+44 (0) 20 7390 0230
|
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.
The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.
The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.